Disease- and transplantation-specific demographics
Characteristic . | No. (%) . |
|---|---|
| Disease | |
| Chronic myeloid leukemia | 93 (22) |
| Acute myeloid leukemia | 102 (24) |
| Acute lymphoblastic leukemia | 103 (24) |
| Other malignant | 101 (24) |
| Nonmalignant | 24 (6) |
| Disease stage (excluding nonmalignant) | |
| Early | 217 (54) |
| Late | 176 (44) |
| Missing | 6 (2) |
| Conditioning regimen | |
| Myeloablative conditioning | 292 (69) |
| Reduced intensity conditioning | 101 (24) |
| No conditioning | 2 (< 1) |
| Missing | 28 (7) |
| Stem cell source | |
| Bone marrow | 348 (82) |
| PBSC | 75 (18) |
| T-cell deletion | |
| Yes | 363 (86) |
| No | 29 (7) |
| Missing | 31 (7) |
| Posttransplantation immunosuppression | |
| Cyclosporin A and methotrexate | 200 (47) |
| Cyclosporin A alone | 138 (33) |
| Other | 12 (3) |
| None | 31 (7) |
| Missing | 42 (10) |
Characteristic . | No. (%) . |
|---|---|
| Disease | |
| Chronic myeloid leukemia | 93 (22) |
| Acute myeloid leukemia | 102 (24) |
| Acute lymphoblastic leukemia | 103 (24) |
| Other malignant | 101 (24) |
| Nonmalignant | 24 (6) |
| Disease stage (excluding nonmalignant) | |
| Early | 217 (54) |
| Late | 176 (44) |
| Missing | 6 (2) |
| Conditioning regimen | |
| Myeloablative conditioning | 292 (69) |
| Reduced intensity conditioning | 101 (24) |
| No conditioning | 2 (< 1) |
| Missing | 28 (7) |
| Stem cell source | |
| Bone marrow | 348 (82) |
| PBSC | 75 (18) |
| T-cell deletion | |
| Yes | 363 (86) |
| No | 29 (7) |
| Missing | 31 (7) |
| Posttransplantation immunosuppression | |
| Cyclosporin A and methotrexate | 200 (47) |
| Cyclosporin A alone | 138 (33) |
| Other | 12 (3) |
| None | 31 (7) |
| Missing | 42 (10) |
PBSC indicates peripheral blood stem cells.